Manuscript no. HAEMATOL/2011/049957 entitled “Deferasirox for up to 3 years leads to continued improvement of myocardial T2* in patients with beta-thalassemia major”

Authors: DJ Pennell, JB Porter, MD Cappellini, LL Chan, A El-Beshlawy, Y Aydinok, H Ibrahim, C-K Li, V Viprakasit, MS Elalfy, A Kattamis, G Smith, D Habr, G Domokos, B Roubert and A Taher

Information about the contributions of each person named as having participated in the study

1) Guarantor(s), i.e., person(s) who is (are) responsible for the integrity of the work as a whole:
• Dudley Pennell, Royal Brompton Hospital, London, United Kingdom. Email: d.pennell@ic.ac.uk

According to the International Committee of Medical Journal Editors (ICMJE) (http://www.icmje.org/ethical_1author.html): “Authorship credit should be based on: 1) substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data; 2) drafting the article or revising it critically for important intellectual content; and 3) final approval of the version to be published. Authors should meet conditions 1, 2, and 3 ……………………
Acquisition of funding, collection of data, or general supervision of the research group alone does not constitute authorship”.

The guarantors of this manuscript confirm that all persons designated as authors qualify for authorship, and that each author has participated sufficiently in the work to take public responsibility for appropriate portions of the content.

2) Authors who participated in the conception of the study: Dudley Pennell (principal investigator), Maria Domenica Cappellini, Amal El-Beshlawy, Chi-Kong Li, Antonis Kattamis (Study monitoring committee overseeing conduct of the trial), John Porter (advisory board) Dany Habr, Gabor Domokos.

3) Design & Methods. The following authors were responsible for specific investigations (please detail):
• Dudley Pennell, John Porter, Maria Domenica Cappellini, Amal El-Beshlawy, Lee Lee Chan, Yesim Aydinok, Mohsen Elalfy, Chi-Kong Li, Hishamshah Ibrahim, Antonis Kattamis, Vip Viprakasit and Ali Taher served as investigators enrolling patients in the trial and were responsible for all investigations.
• Dany Habr and Gabor Domokos coordinated the execution of the trial.

4) Results. The following authors were responsible for specific portions of the results, including figures and tables (please indicate the person responsible for each figure and each table):
• Dudley Pennell and Gillian Smith were responsible for interpreting the CMR results.
• John Porter, Maria Domenica Cappellini, Amal El-Beshlawy, Lee Lee Chan, Yesim Aydinok, Mohsen Elalfy, Chi-Kong Li, Hishamshah Ibrahim, Antonis Kattamis, Vip Viprakasit, Ali Taher, Dany Habr and Gabor Domokos were responsible for data interpretation and reporting of the trial data.
• Bernard Roubert was responsible for the statistical analyses.

5) Writing the manuscript. The following authors were responsible for writing the manuscript:
• Dudley Pennell was responsible for drafting the manuscript;
• all authors critically reviewed the manuscript drafts and approved the final version.
6) Contributors Listed in Acknowledgments:
Helen Little provided medical editorial assistance and financial support for medical editorial assistance was provided by Novartis Pharmaceuticals. The study was sponsored by Novartis Pharma AG.